The FDA has approved fitusiran for bleeding management in hemophilia A or B in patients aged 12 years and older, with or without factor VIII or IX inhibitors. Sanofi, which markets fitusiran as Qfitlia, announced the FDA’s approval in a press release.
Advertisement
Both 10-mg and 25-mg doses proved efficacy in lower rates of pulmonary exacerbations.
Joel Topf spoke with Areef Ishani about kidney stone outcomes from the Diuretic Comparison Project, a study of US veterans.
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
The group delves into a discussion on how measles is not only a national concern but also an international danger.
Joel Topf spoke to Seldin Award winner Roger Rodby at the National Kidney Foundation Spring Clinical Meetings 2025.
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
The Foundation for Sickle Cell Disease Research will evaluate VAS-101 in a phase 1 clinical study.
Malignant neoplasm-associated hemophagocytic lymphohistiocytosis, COVID-19, and CAR T-cell therapy can each initiate CS.
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.